According to study, more than half of those who receive an oral spray-based vaccination can prevent recurrent urinary tract infections (UTIs) for up to nine years. This makes the vaccine a viable substitute for antibiotic treatments.
They can be unpleasant and uncomfortable and affect half of women and one in five men.
Twenty to thirty percent of cases result in recurrent infections that require short-term antibiotic treatment.
There is a need for novel approaches to both prevent and cure UTIs because antibiotic-resistant infections are becoming more common and medications are losing their effectiveness.
A pineapple-flavored suspension is sprayed under the tongue twice a day for three months as part of the MV140 vaccination regimen, which is a novel treatment for recurrent UTIs.
Although the short-term safety and efficacy of MV140 have been investigated before, this is the first global report on a long-term follow-up study.
The study’s co-leader, Dr. Bob Yang, a consultant urologist at the Royal Berkshire NHS Foundation Trust, stated, “All of our patients had recurrent UTIs prior to receiving the vaccination, and these can be challenging to treat for many women.
“This is a veryeasyvaccinetoadministerandcouldbegivenbyGPsasa3-month course. Many of our participants told us that having the vaccine restored their quality of life. While we’re yet to look at the effect of this vaccine in different patient groups, this follow-up data suggests it could be a game changer for UTI prevention if it’s offered widely, reducing the need for antibiotic treatments.”
Patients in the initial experiment were monitored for a full year, and data from the cohort’s female members was released in BJU International in 2017.
The researchers examined information from the electronic health records of their first cohort for their nine-year follow-up analysis.
Participants were questioned about side effects and their experiences with UTIs after getting the vaccination.
During the nine-year follow-up, 48 subjects continued to be completely free of infections. The cohort as a whole experienced an infection-free period of 54.7 months (four and a half years) on average; this was 56.7 months for women and 44.3 months, or one year less, for men.
After a year or two, 40% of participants said they had received additional doses of the vaccination.
Read More: Click Here
